arformoterol

{{Short description|Chemical compound}}

{{Infobox drug

| Verifiedfields = changed

| verifiedrevid = 457140599

| type =

| image = Arformoterol.svg

| image_class = skin-invert-image

| width = 250

| alt =

| image2 = Arformoterol ball-and-stick model.png

| width2 =

| alt2 =

| caption =

| USAN = Arformoterol tartrate

| pronounce =

| tradename = Brovana

| Drugs.com = {{drugs.com|monograph|arformoterol}}

| MedlinePlus = a602023

| DailyMedID = Arformoterol

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = Inhalation

| class =

| ATCvet =

| ATC_prefix = None

| ATC_suffix =

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Brovana- arformoterol tartrate solution | website=DailyMed | date=13 May 2021 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839 | access-date=4 March 2022}}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound = 52–65%

| metabolism =

| metabolites =

| onset =

| elimination_half-life = 26 hours

| duration_of_action =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 67346-49-0

| CAS_supplemental =

| PubChem = 3083544

| IUPHAR_ligand = 7479

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB01274

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 2340731

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = F91H02EBWT

| KEGG = D07463

| KEGG2 = D02981

| ChEBI_Ref = {{ebicite|correct|EBI}}

| ChEBI = 408174

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201137

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

| IUPAC_name = N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide

| C=19 | H=24 | N=2 | O=4

| SMILES =

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1

| StdInChI_comment =

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = BPZSYCZIITTYBL-YJYMSZOUSA-N

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).{{cite journal | vauthors = Loh CH, Donohue JF, Ohar JA | title = Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease | journal = Expert Opinion on Drug Safety | volume = 14 | issue = 3 | pages = 463–72 | date = March 2015 | pmid = 25563342 | doi = 10.1517/14740338.2015.998196 | s2cid = 7767810 }}

It is a long-acting β₂ adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol. It was approved for medical use in the United States in October 2006. It is available as a generic medication.{{cite web | title=Competitive Generic Therapy Approvals | website=U.S. Food and Drug Administration (FDA) | date=29 June 2023 | url=https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals | access-date=29 June 2023 | archive-date=29 June 2023 | archive-url=https://web.archive.org/web/20230629233651/https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals | url-status=dead }}